Grimm, Jonathan and Peschel, Georg and Mueller, Martina and Schacherer, Doris and Wiest, Reiner and Weigand, Kilian and Buechler, Christa (2021) Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. JOURNAL OF CLINICAL MEDICINE, 10 (8): 1621. ISSN , 2077-0383
Full text not available from this repository. (Request a copy)Abstract
Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment. Proprotein convertase subtilisin/kexin 9 (PCSK9) induces degradation of the hepatic LDL receptor and thereby elevates serum LDL. The aim of this study was to determine serum PCSK9 concentrations during and after DAA therapy to identify associations with LDL levels. Serum PCSK9 was increased in 82 chronic HCV-infected patients compared to 55 patients not infected with HCV. Serum PCSK9 was low in HCV patients with liver cirrhosis, but patients with HCV-induced liver cirrhosis still exhibited higher serum PCSK9 than patients with non-viral liver cirrhosis. Serum PCSK9 correlated with measures of liver injury and inflammation in cirrhotic HCV patients. In patients without liver cirrhosis, a positive association of serum PCSK9 with viral load existed. Serum PCSK9 was not different between viral genotypes. Serum PCSK9 did not correlate with LDL levels in HCV patients irrespective of cirrhotic status. Serum PCSK9 was reduced, and LDL was increased at four weeks after DAA therapy start in non-cirrhotic HCV patients. Serum PCSK9 and LDL did not change upon DAA treatment in the cirrhotic group. The rapid decline of PCSK9 after the start of DAA therapy in conjunction with raised LDL levels in non-cirrhotic HCV patients shows that these changes are not functionally related.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LIVER FIBROSIS; DRUG-INTERACTIONS; VIRUS-INFECTION; RISK; STEATOSIS; SEVERITY; PLASMA; OBESE; low-density lipoprotein; liver cirrhosis; Proprotein convertase subtilisin; kexin 9 (PCSK9); hepatitis C; MELD score; genotype |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Aug 2022 12:38 |
| Last Modified: | 29 Aug 2022 12:38 |
| URI: | https://pred.uni-regensburg.de/id/eprint/46462 |
Actions (login required)
 |
View Item |
